Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL.

Phase 3

Recruiting

Conditions: Ph+ ALL

Interventions: Drug: Imatinib
Drug: Olverembatinib

First Posted Date: 2023-09-22

Last Posted Date: 2024-11-07

Lead Sponsor: Ascentage Pharma Group Inc.

Target Recruit Count: 350

Registration Number: NCT06051409

Locations: 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
Alfred Health, Melbourne, Victoria, Australia

and more 11 locations

Exploring the Molecular Mechanism Based on KIT Mutation

Recruiting

Conditions: GIST

Interventions: Drug: Imatinib

First Posted Date: 2023-06-09

Last Posted Date: 2023-06-09

Lead Sponsor: Xijing Hospital

Target Recruit Count: 190

Registration Number: NCT05895942

Locations: 🇨🇳
Xijing Hospital of Air Force Military Medical University, Xi'an, Shaanxi, China

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

Early Phase 1

Suspended

Conditions: Squamous Cell Carcinoma of Head and Neck
Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Imatinib

First Posted Date: 2023-04-18

Last Posted Date: 2024-12-19

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 15

Registration Number: NCT05816785

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Imatinib TDM in GIST

Phase 2

Recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Imatinib

First Posted Date: 2022-08-09

Last Posted Date: 2024-04-01

Lead Sponsor: Reema A. Patel

Target Recruit Count: 28

Registration Number: NCT05493215

Locations: 🇺🇸
Markey Cancer Center, Lexington, Kentucky, United States

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Phase 3

Recruiting

Conditions: Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, BCR/ABL-Positive
Chronic Myeloid Leukemia in Remission

Interventions: Drug: Imatinib
Drug: Asciminib

First Posted Date: 2022-06-10

Last Posted Date: 2023-10-23

Lead Sponsor: Sarit Assouline

Target Recruit Count: 164

Registration Number: NCT05413915

Locations: 🇨🇦
Hôpital Fleurimont - CHUS (CIUSSS Estrie), Sherbrooke, Quebec, Canada
🇨🇦
Clinical Research Unit - Jewish General Hospital, Montreal, Quebec, Canada
🇨🇦
Hôpital Maisonneuve-Rosemont (CIUSSS EMTL), Montréal, Quebec, Canada

and more 1 locations

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Phase 4

Not yet recruiting

Conditions: CML, Chronic Phase

Interventions: Drug: Imatinib
Drug: Flumatinib

First Posted Date: 2022-05-10

Last Posted Date: 2022-05-10

Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Target Recruit Count: 2400

Registration Number: NCT05367765

Locations: 🇨🇳
Institute of Hematology and Oncology, Harbin The First Hospital, Harbin, Heilongjiang, China

Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database

Completed

Conditions: Chronic Myeloid Leukaemia

First Posted Date: 2022-03-18

Last Posted Date: 2023-10-27

Lead Sponsor: Pfizer

Target Recruit Count: 1484

Registration Number: NCT05286528

Locations: 🇭🇺
Pfizer, Budapest, Hungary

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Phase 1

Recruiting

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Pimitespib
Drug: Sunitinib
Drug: Imatinib

First Posted Date: 2022-02-18

Last Posted Date: 2024-08-07

Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Target Recruit Count: 78

Registration Number: NCT05245968

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Fudan University, Shanghai Cancer Center, Shanghai, China
🇯🇵
Kumamoto University Hospital, Kumamoto, Japan

and more 11 locations